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Proton pump inhibitors (PPI) target tumour acidic pH and have an antineoplastic effect in melanoma. The PPI esomeprazole
(ESOM)killsmelanomacellsthroughacaspase-dependentpathwayinvolvingcytosolicacidiﬁcationandalkalinizationoftumour
pH. In this paper, we further investigated the mechanisms of ESOM-induced cell death in melanoma. ESOM rapidly induced
accumulation of reactive oxygen species (ROS) through mitochondrial dysfunctions and involvement of NADPH oxidase. The
ROS scavenger N-acetyl-L-cysteine (NAC) and inhibition of NADPH oxidase signiﬁcantly reduced ESOM-induced cell death,
consistent with inhibition of cytosolic acidiﬁcation. Autophagy, a cellular catabolic pathway leading to lysosomal degradation
and recycling of proteins and organelles, represents a defence mechanism in cancer cells under metabolic stress. ESOM
induced the early accumulation of autophagosomes, at the same time reducing the autophagic ﬂux, as observed by WB analysis
of LC3-II accumulation and by ﬂuorescence microscopy. Moreover, ESOM treatment decreased mammalian target of rapamycin
signalling,asreducedphosphorylationofp70-S6Kand4-EBP1wasobserved.InhibitionofautophagybyknockdownofAtg5and
Beclin-1expressionsigniﬁcantlyincreasedESOMcytotoxicity,suggestingaprotectiveroleforautophagyinESOM-treatedcells.
The data presented suggest that autophagy represents an adaptive survival mechanism to overcome drug-induced cellular
stress and cytotoxicity, including alteration of pH homeostasis mediated by proton pump inhibition.
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The biochemical and physical properties of the tumour
microenvironment represent crucial factors that govern
tumour progression and drive the selection of malignant
cells.
1 Tumour acidity is an inevitable consequence of the
upregulated glycolytic ﬂux induced by hypoxia, and dramati-
cally affects cancer progression and sensitivity to therapy.
2–4
An important feature of the tumour microenvironment is
alteration of pH gradients the regulation of which is ﬁnely
mediated by ion pumps such as vacuolar ATPase
(V-ATPase), Na
þ/H
þ exchanger and carbonic anhydrases.
Increasedacidproductionfollowingmetabolicreprogramming
of cancer cells results in acidiﬁcation of extracellular pH (pHe)
and alkalinization of intracellular/cytosolic pH (pHi).
5–8 Acido-
sis is indeed a hallmark of cancer and exerts a selective
pressure driving malignant progression; it is also involved
in metastatic potential, invasiveness and resistance to
therapy.
8–15 Thus, agents altering tumour pH homeostasis
exert antitumour effects by inducing reversion of drug
resistance and inhibiting tumour growth and metastatic
progression.
11,16–19
The V-ATPase is a proton pump translocating protons
across membranes, thus acidifying the lumen of endolyso-
somal organelles and the extracellular environment in certain
specialized cells.
5 The role of V-ATPase in tumour progres-
sion is supported by its increased activity and expression in
metastatic tumours.
20 In fact, inhibition of V-ATPase reduces
tumour growth and metastatic spread, thus representing a
suitable therapeutic target.
13,18 Several studies have shown
that proton pump inhibitors (PPIs) such as omeprazole,
esomeprazole (ESOM) and pantoprazole have an antineo-
plastic activity towards human hematopoietic and solid
tumours. PPI revert chemoresistance in drug-resistant
tumours and directly induce tumour cell killing.
11,17,21,22 PPI
treatment disturbs tumour pH gradients with major conse-
quences on drug retention and trafﬁc of acidic vesicles
in human melanoma and gastric adenocarcinoma.
17
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www.nature.com/cddisRecently, we reported that PPI have a caspase- and
pH-dependent antineoplastic activity in human melanoma
and that treatment of human melanoma xenografts with PPI
reduces tumour growth through a dramatic disturbance of
tumour pH homeostasis.
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Autophagy is a tightly regulated catabolic mechanism used
by eukaryotic cells to degrade long-lived proteins and
organelles.
23 The autophagic pathway starts with the forma-
tion of isolation membranes that elongate to form the
autophagosome, a double-membrane vesicle that sequesters
cytoplasmic material. After fusion of autophagosomes with
lysosomes, the autophagic cargo is degraded and recycled
back to the cytoplasm.
24 Acidic organelles such as lysosomes
and autophagic vacuoles may have a key role in tumour
malignancy,and modulation ofautophagy hasbeen proposed
as possible anticancer strategy. However, autophagy may
have both tumour-suppressing and tumour-promoting roles,
making it complex to identify strategies to target autophagy in
cancer therapy.
25 We previously showed that PPI cause
alkalinization of lysosomal pH and induce reactive oxygen
species (ROS) in B-cell tumours;
17,22 both these events are
known to modulate autophagy.
Inthis study,weusedhuman melanomacell linestoidentify
the upstream mechanisms mediating the antineoplastic effect
of ESOM. We found that ESOM induced a ROS-dependent
cell death and that autophagy represents an adaptive
response to oxidative stress induced by ESOM in human
melanoma cells.
Results
ESOM induces ROS-dependent cell death in human
melanoma. We reported that targeting tumour acidic pH by
ESOM induced cell death in human melanoma through a
caspase-dependent pathway and reduced tumour growth in
SCID mice engrafted with human melanoma.
22 ESOM
cytotoxic effects were detected in unbuffered culture
conditions and dramatically enhanced in acidic culture
conditions. Here, we evaluated which upstream events
triggered ESOM-induced cell death in human melanoma.
Treatment with ESOM rapidly induced accumulation of
hydrogen peroxide and superoxide radicals in melanoma
cells, as shown by DHR123 and HE ﬂuorescence,
respectively (Figure 1a).
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Figure 1 ESOM induces ROS and mitochondrial alterations in human melanoma. (a) ESOM (160mM) induces accumulation of hydrogen peroxide and superoxide
radicals,asshownbyDHR123andHEﬂuorescence,respectively.Inthehistogram,untreatedMe30966cellsareindicatedbythedottedlineandcellstreatedwithESOMafter
1,2and4hareindicatedwithblackline,lightgreyanddarkgreyhistograms,respectively.(b)ESOM-inducedROSaccumulationisinhibitedbyboththeROSscavengerNAC
and the NADPH oxidase inhibitor DPI in Me30966 cells. (c) Me30966 cells treated with ESOM (160mM) for 5h show mitochondrial membrane depolarization detected by
TMRE probe. Black, red and green lines indicate untreated, ESOM-treated and staurosporine-treated cells, respectively. (d) Me30966 cells treated with ESOM (160mM) for
2,4and6hwereprocessedtopurifythecytosolicandmitochondrialfractions.ExpressionofcytochromecwasassessedbyWBandindicatesatime-dependentreleaseofthe
protein from the mitochondria into the cytosol. The Red Ponceau staining indicates equal loading of proteins, whereas purity of the fractions was assessed by proibitin
expression
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Cell Death and DiseaseThe major sources of intracellular ROS are mitochondria
and NADPH oxidase and we analysed their possible involve-
ment in driving ESOM-mediated ROS accumulation. First,
we observed that diphenylene-iodonium (DPI), a speciﬁc
pharmacological inhibitor of NADPH oxidase, and the
commonROS scavenger N-acetyl-L-cysteine (NAC) signiﬁcantly
reduced ROS accumulation in cells treated with ESOM
(Figure 1b). Moreover, TMRE staining after ESOM treatment
showed depolarization of mitochondrial membrane
(Figure 1c), whereas release of cytochrome c from mitochon-
dria and its accumulation in the cytosolic fraction were
observed by western blot in a time-dependent manner and
within 6h after treatment (Figure 1d). These experiments
indicate that both mitochondria and NADPH oxidase partici-
pate in ROS induction by ESOM in human melanoma cells.
We evaluated the involvement of ROS in ESOM-induced
apoptosis in Me30966 and Mel501. These cells pretreated
with NAC (5mM) were completely protected from cell death
induced by 100mM H2O2 (data not shown). As shown in the
morphological analysis of Me30966 cells (Figure 2a),
pretreatment with NAC completely abrogated ESOM-induced
cell death in both Mel501 and Me30966 cells (Figure 2b). As we
reported that ESOM-induced apoptosis is caspase dependent,
weobservedherethattheinhibitionofapoptosisinthepresence
of NAC was associated with decreased percentage of cells with
active caspase-3 and caspase-8 (Figure 2c). We also observed
that inhibition of NADPH oxidase by DPI induced a signiﬁcant
reduction of ESOM-induced cell death in Me30966 cells
(Supplementary Figure 1a).
PPI are known to induce cytosolic acidiﬁcation in
cancer cells
11,22 and we found that ESOM-induced
acidiﬁcation of cytosolic pH was signiﬁcantly prevented
by NAC in Me30966 cells (Figure 2d, Po0.01), suggesting
that ROS production is an early event upstream of ESOM
effects on cytosolic pH and alteration of intracellular pH
gradients.
ESOM induces the accumulation of autophagic vacuoles
in melanoma cells. It is known that ROS are involved in the
autophagic response of cancer cells to nutrient starvation or
metabolic stress.
26 Moreover, PPIs have been reported to
cause alkalinization of lysosomal pH (Supplementary
Figure 1b) and disturbance of acidic vesicle trafﬁc. As
proper lysosomal function and ROS are crucial autophagy
regulators, we investigated whether ESOM-induced
cytotoxicity involved alteration in the autophagic pathway.
ESOM-treated cells showed massive vacuolization
(Figure 3a, upper panel), which has been reported to occur
in cells before apoptosis.
27 Electron microscopy experiments
showed that treatment of Me30966 with ESOM leads to an
increased number of autophagic vacuoles per cell as
compared with untreated cells (Figure 3a, middle and lower
panels). To evaluate autophagy, we looked at the cellular
distribution of the microtubule-associated protein 1 light
chain 3 (LC3), a marker of autophagy. In conditions of
autophagy activation, cytosolic LC3 is conjugated to
phosphatidylethanolamine (LC3-II) and localizes to auto-
phagosomes. Therefore, the number of LC3-positive vesicles
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Figure 2 Involvement of ROS in ESOM-induced cell death. (a) The presence of NAC protects Me30966 cells from ESOM-induced cell death as observed by light
microscopy. (b and c) ROS scavenging by NAC inhibits ESOM-induced apoptosis and caspase activation in both Me30966 and Mel501 cells. (d) ESOM-induced cytosolic
acidiﬁcation is inhibited by NAC in Me30966 cells treated with ESOM for 6h. In all these experiments, 160mM ESOM was used
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Cell Death and Diseaseand the amount of LC3-II are commonly used as a measure
of autophagosome formation.
28 Following cell transfection
with GFP-LC3-expressing plasmid, ESOM strongly
enhanced the appearance of punctuate ﬂuorescence in
Me30966 (Figure 3b, lower panel) and WM793 cells,
indicating a redistribution of LC3 to autophagic vacuoles
with respect to untreated cells. Quantitative evaluation of
cells carrying GFP-LC3-positive dots showed that ESOM
treatment signiﬁcantly increased the percentage of cells
carrying autophagosome markers (Figure 3b, upper panel).
Similar results were observed on Me30966 cells when
endogenous LC3 ﬂuorescence pattern was analysed
(Supplementary Figure 1c).
ESOM induces autophagosome accumulation and slows
down the autophagic ﬂux. Increased autophagosome
markers may be explained by increased autophagosome
formation due to induction of autophagic activity, or
accumulation of autophagic organelles due to impaired
degradation of autolysosome content. Autophagic ﬂux may
be measured by the levels of LC3-II degraded in
autolysosomes in which lysosomal hydrolases are
functional.
28 Thus, the status of autophagic ﬂux in
Me30966 cells was analysed in the presence or absence
of lysosomal protease inhibitors (E64d/Pepstatin A). First,
we observed that these cells are fully competent for
starvation-induced autophagy (Supplementary Figure 1d).
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Figure 3 Effects of ESOM on autophagic ﬂux. (a) Me30966 cells treated with ESOM (160mM) for 8h are characterized by massive intracellular vacuolization.
(b) Treatment with ESOM (for 8h) induces accumulation of LC3-positive autophagic vacuoles in Me30966 and WM793 cells. (c) ESOM induces accumulation of the LC3-II
form in autophagy-competent melanoma cells, as shown by the further accumulation of LC3-II in cells pretreated with inhibitors of lysosomal proteases. (d) ESOM-induced
alterationoftheautophagicﬂuxisconﬁrmedbyaccumulationofp62.(eandf)AnalysisofthemRFP-GFP-LC3-plasmidshowstheaccumulationofautophagosomesinESOM-
treated Me30966 cells. Cells cultured in EBSS were used as positive control
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Cell Death and DiseaseWe observed that ESOM induced a time-dependent
accumulation of LC3-II in Me30966 cells (Figure 3c), which
was further enhanced in the presence of E64d/PepA,
supporting the notion that, in cells treated with ESOM, the
autophagic ﬂux is not blocked. However, the effect of
lysosomal inhibitors on LC3-II accumulation in control cells
is increased with respect to ESOM-treated cells, also
indicating that ESOM partially reduces the autophagic ﬂux
(Supplementary Figure 1e). These ﬁndings suggest that
ESOM likely causes the accumulation of autophagosomes
and slows down the autophagic ﬂux. In line with the
accumulation of LC3-II, Me30966 cells treated with ESOM
showed accumulation of p62 detected as early as 4h after
treatment (Figure 3d).
These data were further conﬁrmed by the analysis of cells
transfected with an mRFP-GFP-LC3-expressing plasmid.
This probe allows distinguishing between autophagosomes
(GFPþRFPþ yellow puncta) and autolysosomes (GFP-
RFPþ red puncta), as the GFP ﬂuorescence is quenched in
the acidic lumen of autolysosomes.
28 In fact, ESOM-treated
cells carried an increased number of dots with RFPþGFPþ
ﬂuorescence with respect to untreated cells (Figure 3e and f),
whereas the number of RFPþGFP  dots was not affected,
suggesting that ESOM induces the accumulation of auto-
phagosomes as it slows down the autophagic ﬂux.
As ESOM-induced cell death was mediated by massive
ROSproduction,weevaluatedtheeffectsofROSinhibitionon
ESOM-induced alterations in the autophagic ﬂux. The
expression and localization of endogenous LC3 in Me30966
cells was studied by laser scanning confocal microscopy
(LSCM) analysis. Basal levels of LC3-positive autophagic
vesicles were signiﬁcantly increased 8h after ESOM treat-
ment, with a signiﬁcant proportion of cells showing a clear
punctuate ﬂuorescence (Figure 4a and b). The presence of
lysosomal protease inhibitors did not signiﬁcantly affect
ESOM-induced accumulation of endogenous LC3 dots,
conﬁrming that ESOM partially reduces the autophagic ﬂux
(Figure 4a and b). Conversely, pretreatment with NAC
prevented the accumulation of LC3-positive dots induced by
ESOM (Figure 4a and b) and inhibited LC3-II (Figure 4c),
suggesting that ROS are involved in ESOM-induced accu-
mulation of autophagosomes in melanoma cells.
ESOM inhibits the mammalian target of rapamycin
(mTOR)-signalling pathway. An important pathway
regulating autophagy is the signalling through the mTOR,
the inhibition of which activates autophagy in cells under
nutrient starvation.
29 Decreased mTOR signalling can be
evaluated by the reduced phosphorylation of p70-S6K and
4EBP1, which are two important downstream targets of
mTOR. We observed that, in Me30966 cells treated with
ESOM, the phosphorylation of both p70-S6K and 4EBP1 was
decreased in a time-dependent manner and with similar time
kinetics (Figure 4d). In line with the role of ROS in driving
autophagy, we observed that the inhibition of mTOR activity
was prevented by ROS scavenging, as the presence of NAC
partially restored the phosphorylation of both 4EBP1 and p70
(Figure 4e). These ﬁndings further conﬁrm that ESOM
induces the accumulation of autophagosomes and
suggests that inhibition of the mTOR signalling pathway
may drive the autophagic response induced by ESOM in
melanoma cells.
Inhibition of autophagy increased PPI cytotoxicity
in melanoma cells. To analyse the role of autophagy
in ESOM-induced cell death, we measured cell death in
Me30966 and WM793 cells in which autophagy was inhibited
by knockdown of Beclin-1 or Atg-5 gene expression or by
inhibition of autolysosome formation by Baf-A1. First, we
observed that pretreatment of melanoma cells Me30966 with
Baf-A1 signiﬁcantly increased the cytotoxicity of ESOM in
melanoma cells (Figure 5a). In line with this result, we
observed that, in ESOM-treated Me30966 cells, there is an
increased accumulation of LC3-II in the presence of Baf-A1.
However, the effect of Baf-A1 in ESOM-treated cells
was reduced when compared with control cells, further
conﬁrming that ESOM also slows down the autophagic ﬂux
(Figure 5a). We then measured ESOM-induced cell death in
Me30966 and WM793 cells, in which the autophagic genes
Atg5 and Beclin-1 were silenced. Knockdown of Atg5 and
Beclin-1 decreased protein expression (Supplementary
Figure 2A) and inhibited the formation of LC3þ puncta in
GFP-LC3-transfected cells, as shown for Me30966 cells
(Figure 5b).
Interestingly, knockdown of Atg5 (and to a lesser extent
Beclin-1)increasedESOM-inducedcelldeathinbothcelllines
(Figure 5c and d) and also in Mel501 cells (not shown),
strongly indicating that autophagy (and autophagosome
formation) may represent an adaptive survival mechanism
used by melanoma cells in response to ESOM insult.
Discussion
The acidic pH of solid tumour tissues has been proposed as a
therapeutic target and a drug delivery system for selective
anticancer treatments.
6,8,13,30,31 Inhibition of several proton
extrusion mechanisms adopted by malignant cancer cells
represents one promising therapeutic strategy
6–8 and PPI
treatment has been proposed as a valid and feasible
approach because of the relatively low toxicity and potential
selectivity of these drugs.
8,11,32 The antitumour activities of
PPI include both, their ability to revert chemoresistance of
drug-resistant tumours and their capacity to induce tumour
cell killing.
11,21,22 Preclinical studies reported recently by our
group
11,17,22 have provided the ground for currently ongoing
phase II clinical trials evaluating ESOM, both in combination
therapy and as a ﬁrst-line treatment of metastatic melanoma,
breast carcinoma and osteosarcoma in Italy and China.
Interestingly, the pharmacological and chemical properties of
PPI make these acid-activated prodrugs as ideal drugs for
selective delivery at the acidic tumour site, where, once
activated, they may exert their antineoplastic activity.
11 In line
with the feasibility of such an approach, a chemically modiﬁed
omeprazole containing a NAC molecule (NACO) to increase
bioavailability has been reported to induce apoptosis in
human melanoma.
33 Recently, we have reported in a
preclinical model of human melanoma that ESOM treatment
exerts a pH-dependent antineoplastic activity through its
ability to severely disturb tumour pH homeostasis.
11 The
proapoptotic effects of ESOM were mediated by the induction
PPI induces autophagy in human melanoma
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Cell Death and Diseaseofacaspase-dependentpathwayandacidiﬁcationofcytosolic
pH. The aim of the current study was to further dissect the
molecular and biochemical pathways activated in human
melanoma cells treated with PPI (summarized in Figure 6).
PPIs have been previously shown to induce caspase-
independent and partially ROS-dependent cell death in
human B-cell tumours.
22 Conversely, PPIs induce a cas-
pase-dependent cell death in human melanoma
11 and we
reported here that accumulation of ROS is instrumental for
ESOM-mediated cell death in human melanoma. Both
mitochondrial and NADPH oxidase seemed to be involved in
triggering ROS accumulation in ESOM-treated cells. Besides
their function in triggering apoptosis, ROS may function as
important signalling molecules in starvation-induced auto-
phagy,
26 and it was recently shown that ROS production
induced by NADPH oxidase activates antibacterial autophagy
in phagocytes,
34 suggesting a role for NADPH oxidase in
autophagy regulation. Indeed, we found a time-dependent
induction of autophagy in ESOM-treated human melanoma
cells, and inhibition of ROS by a ROS scavenger completely
inhibited both apoptosis and autophagosome accumulation.
Targeting the autophagy regulation of cancer cells is a
therapeutic strategy yet to be properly designed. In fact, the
role of autophagy in cancer development, malignant progres-
sion and therapy is still under investigation.
25,29 Despite the
initial observation that the ATG gene Beclin-1 functioned as a
tumour suppressor,
35 several studies have suggested that
autophagy may also function as a survival mechanism
adopted by cancer cells facing hostile microenvironment
conditions (such as hypoxia) and the resultant metabolic
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Cell Death and Diseasestress. Moreover, many currently used anticancer agents are
able to induce the accumulation of autophagosomes in vitro,
which likely represents a protective mechanism against the
stress induced by cytotoxic agents.
23–25 It has been recently
reported that autophagy is activated in tumour cells that
surviveapoptosisfollowingtherapeuticstress.
36Inthismodel,
cloroquine treatment inhibited autophagy-dependent survival
of tumour cells, indicating that autophagy may contribute to
the selection of cells surviving chemotherapy. Interestingly,
cloroquine is a lysosomotropic agent that raises lysosomal pH
and induces accumulation of autophagosomes.
37 Similarly,
siramesine was reported as a lysosomotropic compound able
to induce cytoprotective autophagosome accumulation in
breast carcinoma cells.
38 Interestingly, several PPIs (ome-
prazole, ESOM and pantoprazole) raise lysosomal pH and
decrease intracellular pH, a feature associated with their
ability to sensitize cancer cells to chemotherapeutics as well.
We found that in human melanoma cells in which autophagy
was downregulated through gene silencing, the proapoptotic
effects of ESOM were signiﬁcantly enhanced, supporting
evidence that an intact autophagic pathway is necessary to
overcome ESOM cytotoxicity and that induction of autophagy
in these cells represents an adaptive survival mechanism to
ESOM-induced damage. In agreement with this, the analysis
of cells collected at the end of a clonogenic survival assay in
three melanoma cells lines strikingly indicated induction of
autophagy (detected as LC3-II accumulation) in colonies
surviving ESOM treatment (Supplementary Figure 2C and D).
Recently, the polyphenol kaempferol has been reported to
trigger a ROS-dependent and caspase-dependent cell death
in HeLa cells and these cells activate autophagy as a survival
mechanism to the drug-induced bioenergetics failure.
39
Moreover, desmethylclomipramine (the active metabolite of
a drug used for the treatment of psychiatric disorders) was
found to increase autophagosomal markers and block the
degradation of autophagic cargo in HeLa cells.
40 Treatment
with desmethylclomipramine potentiated the cytotoxic effects
of doxorubicin on HeLa cells through inhibition of the
autophagic pathway. In light of the reported ability of PPI to
revert chemoresistance of tumour cells,
19,26,29 it is concei-
vable that this effect may be mediated by the inhibition of
autophagy that we described here.
In conclusion, we report that treatment with ESOM induces
a ROS-dependent cell death in human melanoma and that
these cells use the autophagic pathway as a defence and
adaptive mechanism. The ﬁndings reported in this study
provide the rationale for possible combination therapies
including PPI and other autophagy inhibitors for the treatment
of melanoma.
Materials and Methods
Reagents. ESOM sodium salt (AstraZeneca, Mo ¨lndal, Sweden) was
resuspended 2 mg/ml in 0.9% NaCl (saline) immediately before use. Baﬁlomycin
A1 (Baf-A1), hydrogen peroxide, NAC, DPI, E64d and phosphate-buffered saline
(PBS) were from Sigma (Milano, Italy). RPMI 1640, antibiotics and fetal calf serum
(FCS)werefromCambrex(Milano,Italy).PepstatinAandFugenewerefromRoche
Applied Science (Milano, Italy). Dihydrorhodamine 123 (DHR123), dihydroethidium
(HE) and lipofectamine 2000 were from Invitrogen (Milano, Italy). The following
antibodies were used: p70S6K, phospho-p70S6K, 4EBP1 and phospho-4EBP1
(Cell Signaling Technology, Milano, Italy), p62 (BD Transduction Laboratories,
Milano, Italy), Beclin-1 and Atg5 (Santa Cruz Biotechnology, USA), b-actin (Cell
Signaling Technology), antirabbit and antimouse-HRP-conjugated antibodies
(Amersham Biosciences, Milano, Italy). Anti-LC3 antibody against a synthetic
LC3 peptide was produced in rabbits by NeoMPS (Strasbourg, France). The GFP-
LC3 plasmid and the mRFP-GFP-LC3 plasmid were kind gifts from Dr. Tamotsu
Yoshimori (National Institute of Genetics, Mishima, Japan).
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Cell Death and DiseaseCell culture. Human melanoma cell lines Me30966, Mel501 and WM793 (a gift
fromDr.MeenhardHerlyn,WistarInstitute,PA,USA)wereculturedwithRPMI1640
in the presence of 10% FCS and antibiotics. Experiments were performed in
unbuffered medium (without sodium bicarbonate).
Celldeathdetermination. Cellswereseededat15000–40000cellsperwell
in 6-or 12-well plates in duplicate wells. The next day, ESOM was added at indicated
concentrations and 24h later cells were collected for analysis. Determination of cell
death was performed by annexin-V-FITC and propidium iodide staining, following the
manufacturer’s instructions (Alexis Biochemicals, Firenze, Italy). Cells showing
positivity for annexin-V binding were deﬁned as apoptotic. Cells were sorted on a
Becton Dickinson FACScan machine and analysed using CellQuest software (Becton
Dickinson Systems, Milano, Italy). At least 10000 cells per sample were acquired.
Analysis of oxidative stress. Detection of ROS was evaluated on
0.25 10
6 cells at different time points after ESOM treatment. Hydrogen
peroxide (100mM) was used as positive control for induction of ROS. HE and
DHR123 were used to detect superoxide radicals and hydrogen peroxide,
respectively. After treatment, cells were incubated with 10mM HE or DHR123 in
FCS-free RPMI for 10min at 371C and immediately analysed by FACS, collecting
the ﬂuorescence into FL3 and FL1 channels, respectively.
Westernblot. Cells werecollectedand treatedwith RIPA buffer(150mM NaCl,
50mM Tris with pH 7.4, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate)
supplemented with protease and phosphatase inhibitors, and protein concentration
of cellular extracts was determined by Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA, USA). SDS-PAGE was performed on acrylamide gels (12–15%)
loading 30mg of proteins per lane. After electrophoresis, proteins were transferred to
PVDF membranes and incubated for 2h at RT in PBS with 5% non-fat dry milk.
Protein loading was assessed by Red Ponceau staining of the membranes.
Membranes were incubated with primary antibodies overnight at 41C, followed by
appropriate HRP-conjugated secondary antibodies. Antibody staining was visualized
by the ECL system (Pierce, Rockford, IL, USA).
LSCManalysis. Cellculturemonolayerswereﬂattenedoveraglassslide,ﬁxed
with 4% paraformaldehyde and treated brieﬂy with 0.1M glycine in PBS (pH 7.4),
followed by 0.3% Triton X-100 buffer. Cells were later stained with anti-LC3 Ab
(1:200) overnight at 41C and then with Alexa Fluor 488-conjugated antirabbit Ab
(1:200) for 1h at RT. TOTO-3 iodide (642/660) (Invitrogen) was used for nuclei
staining. Glass slides were washed and mounted with 95% glycerol in PBS.
Confocal microscopy was carried out on a Radiance 2100 laser scanning confocal
microscope (Bio-Rad Laboratories) equipped with a krypton/argon laser and a red
laser diode. To reduce bleedthrough, confocal images were acquired sequentially.
Noise reduction was achieved by ‘Kalman ﬁltering’ during acquisition.
Transmission electron microscopy analysis. Samples were ﬁxed with
4% paraformaldehyde and 2% glutaraldehyde in 0.12M phosphate buffer and
postﬁxed with 1% OsO4 in cacodylate buffer, dehydrated in ethanol and embedded in
epoxy resin. Ultrathin sections (60nm), obtained with ultramicrotome Ultracut E
Reichert-Jung (Depew, NY, USA), were doubly stained with uranyl acetate and lead
citrate and examined by transmission electron microscope CM 10 Philips (FEI,
Eindhoven, the Netherlands).
Evaluation of autophagy. pEGFP-LC3 plasmid and the mRFP-GFP-LC3
plasmidwere used. At 24h afterplating, the cells weretransfected with either of the
plasmids by using lipofectamine 2000 or Fugene. The next day, cells were treated
for 8–24h with ESOM in unbuffered medium. Cells were then ﬁxed using 2%
paraformaldehyde, and autophagy was determined by quantiﬁcation of the number
of cells with LC3-positive organelles, counting at least 100 cells in triplicate per
condition. The presence of autophagic vacuoles expressing endogenous LC3 was
also assessed.
RNA interference of autophagic genes. Small interfering RNAs (siRNA)
for Atg5 and Beclin-1 were synthesized by Dharmacon RNA Technologies (Milano,
Italy) (siGENOME SMART pool). For siRNA transfection, Me30966 and WM793
cellswereseededin unbufferedmediumat 30% conﬂuencein 12-welltissuedishes
transfected with 5nM of speciﬁc siRNA by using Interferin (PolyPlusTransfection,
Lafayette, CO, USA) following themanufacturer’sprotocol. The silencingefﬁcacy of
the various siRNAs was assessed by WB analysis of Atg5 and Beclin-1 proteins
using polyclonal antibodies. At 48h after transfection, ESOM (160mM) was added
and cells analysed for apoptosis.
Statistical analysis. Differences between groups were analysed by the
Mann–Whitney test, Student’s t-test or by one-way analysis of variance as
appropriate. Data in the text are expressed as mean±S.D. and the P-values
reported are two-sided.
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